Adiponectin gene polymorphisms and susceptibility to atherosclerosis: A meta-analysis
Marjan Mansourian1, Shaghayegh Haghjooy Javanmard2
1Department of Biostatistics, School of Health, Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Summary
The Adiponectin (ADIPOQ) 276G/T polymorphism is not linked to atherosclerosis risk. This meta-analysis of nine studies found no significant association, indicating further high-quality research is needed.
Area of Science:
- Genetics and Cardiovascular Disease
Background:
- Previous studies on the Adiponectin (ADIPOQ) 276G/T polymorphism and atherosclerosis risk have yielded inconclusive results.
- The ADIPOQ gene plays a role in metabolic and cardiovascular health, making its polymorphisms potential risk factors for atherosclerosis.
Purpose of the Study:
- To investigate the association between the ADIPOQ +276 G > T polymorphism (rs1501299) and the risk of developing atherosclerosis.
- To synthesize existing evidence through a meta-analysis to clarify the relationship between this specific ADIPOQ polymorphism and atherosclerosis.
Main Methods:
- A comprehensive literature search was conducted to identify relevant studies.
- A meta-analysis was performed using fixed-effect models to calculate pooled odds ratios (OR) and 95% confidence intervals (CI).
- Heterogeneity was assessed using the Q test and I² statistics, and publication bias was evaluated using Egger's regression test and funnel plots.
Main Results:
- Nine studies comprising 1959 cases and 3739 controls were included in the meta-analysis.
- The ADIPOQ 276G/T polymorphism showed no significant association with atherosclerosis risk (TT vs. GG: OR=0.925, 95% CI: 0.728-1.178; TG vs. GG: OR=0.921, 95% CI: 0.804-1.054).
- No significant between-study heterogeneity or publication bias was detected.
Conclusions:
- This meta-analysis concludes that the ADIPOQ 276G/T polymorphism is not associated with atherosclerosis.
- Further high-quality studies are warranted to definitively establish the role of ADIPOQ polymorphisms in atherosclerosis development.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
948
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
948
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K